These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1387 related items for PubMed ID: 16551863

  • 1. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.
    Clin Cancer Res; 2006 Mar 15; 12(6):1785-93. PubMed ID: 16551863
    [Abstract] [Full Text] [Related]

  • 2. Is BRAF the Achilles' Heel of thyroid cancer?
    Chiloeches A, Marais R.
    Clin Cancer Res; 2006 Mar 15; 12(6):1661-4. PubMed ID: 16551846
    [No Abstract] [Full Text] [Related]

  • 3. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD.
    J Clin Endocrinol Metab; 2007 Dec 15; 92(12):4712-8. PubMed ID: 17878251
    [Abstract] [Full Text] [Related]

  • 4. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1623-9. PubMed ID: 16533790
    [Abstract] [Full Text] [Related]

  • 5. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
    Liu D, Liu Z, Jiang D, Dackiw AP, Xing M.
    J Clin Endocrinol Metab; 2007 Dec 01; 92(12):4686-95. PubMed ID: 17911174
    [Abstract] [Full Text] [Related]

  • 6. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA.
    Cancer Res; 2008 Aug 01; 68(15):6145-53. PubMed ID: 18676837
    [Abstract] [Full Text] [Related]

  • 7. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Knauf JA, Zhang L, Taira K, Fagin JA.
    Endocrinology; 2006 Feb 01; 147(2):1014-9. PubMed ID: 16254036
    [Abstract] [Full Text] [Related]

  • 8. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
    Mesa C, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA.
    Cancer Res; 2006 Jul 01; 66(13):6521-9. PubMed ID: 16818623
    [Abstract] [Full Text] [Related]

  • 9. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim JA, Kim WB, Shong YK.
    J Endocrinol; 2011 Oct 01; 211(1):79-85. PubMed ID: 21795305
    [Abstract] [Full Text] [Related]

  • 10. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H, Nakamura Y, Yasuoka H, Zhang P, Nakamura M, Mori I, Miyauchi A, Kakudo K.
    Pathol Int; 2007 Jan 01; 57(1):12-20. PubMed ID: 17199737
    [Abstract] [Full Text] [Related]

  • 11. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R, Cignarelli M, Landriscina M.
    J Clin Endocrinol Metab; 2012 Jun 01; 97(6):E898-906. PubMed ID: 22442268
    [Abstract] [Full Text] [Related]

  • 12. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades N.
    Mol Cancer Ther; 2007 Mar 01; 6(3):1070-8. PubMed ID: 17363500
    [Abstract] [Full Text] [Related]

  • 13. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.
    Cancer Res; 2009 Nov 01; 69(21):8317-25. PubMed ID: 19861538
    [Abstract] [Full Text] [Related]

  • 14. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
    Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.
    J Pathol; 2009 Apr 01; 217(5):707-15. PubMed ID: 19156774
    [Abstract] [Full Text] [Related]

  • 15. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
    Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G.
    J Clin Endocrinol Metab; 2010 Jan 01; 95(1):450-5. PubMed ID: 19880792
    [Abstract] [Full Text] [Related]

  • 16. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
    Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA.
    J Clin Endocrinol Metab; 2008 Jun 01; 93(6):2194-201. PubMed ID: 18381570
    [Abstract] [Full Text] [Related]

  • 17. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC, Fredrick MJ, Clayman GL.
    Arch Otolaryngol Head Neck Surg; 2007 Aug 01; 133(8):810-5. PubMed ID: 17709622
    [Abstract] [Full Text] [Related]

  • 18. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
    Arthan D, Hong SK, Park JI.
    Cancer Lett; 2010 Nov 01; 297(1):31-41. PubMed ID: 20570039
    [Abstract] [Full Text] [Related]

  • 19. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.
    J Clin Endocrinol Metab; 2011 Jan 01; 96(1):E19-30. PubMed ID: 20926530
    [Abstract] [Full Text] [Related]

  • 20. Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation.
    Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, Ahn SH.
    Cancer Biol Ther; 2011 Sep 01; 12(5):458-65. PubMed ID: 21725210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.